Literature DB >> 2588211

Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms.

E L Ong1, M E Ellis, A K Webb, K R Neal, M Dodd, E O Caul, S Burgess.   

Abstract

Thirty six adults with cystic fibrosis were studied over one year to determine the incidence of infection with respiratory viruses and atypical organisms. Nineteen patients entered the study during an acute exacerbation of respiratory symptoms with an increase in purulent sputum production, cough, or breathlessness accompanied by a fall in FEV1 (group 1); 17 patients entered when they were stable both clinically and in terms of lung function values (group 2). Group 1 patients had a mean of 2.6 (range 1-4) infective exacerbations during the year and group 2 patients a mean of 1.1 (0-2) exacerbations. Eleven patients developed serological evidence of viral (influenza virus A and B, cytomegalovirus, human rhinovirus 2, adenovirus) or Mycoplasma pneumoniae infection. There was no difference in seroconversion rates between group 1 (five patients) and group 2 (six patients). There was a weak association between viral seroconversion and the isolation of Pseudomonas aeruginosa from sputum, though this was not significant.

Entities:  

Mesh:

Year:  1989        PMID: 2588211      PMCID: PMC462055          DOI: 10.1136/thx.44.9.739

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  The flora of the respiratory tract of patients with cystic fibrosis of the pancreas.

Authors:  N N HUANG; E L VAN LOON; K T SHENG
Journal:  J Pediatr       Date:  1961-10       Impact factor: 4.406

2.  Cystic fibrosis of the pancreas.

Authors:  D H ANDERSEN
Journal:  J Chronic Dis       Date:  1958-01

3.  Bacterial infection in cystic fibrosis.

Authors:  J R May; N C Herrick; D Thompson
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

4.  The use of a radial haemolysis test for neuraminidase antibodies in the diagnosis of influenza A infection.

Authors:  E A Grilli; A J Smith
Journal:  J Hyg (Lond)       Date:  1983-08

5.  Respiratory viruses in cystic fibrosis.

Authors:  M I Marks
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

6.  Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis.

Authors:  P F Wright; K T Khaw; M N Oxman; H Shwachman
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

7.  Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa.

Authors:  N T Petersen; N Høiby; C H Mordhorst; K Lind; E W Flensborg; B Bruun
Journal:  Acta Paediatr Scand       Date:  1981-09

8.  Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

Authors:  E E Wang; C G Prober; B Manson; M Corey; H Levison
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

9.  A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.

Authors:  P A Gross; F A Ennis; P F Gaerlan; L J Denson; C R Denning; D Schiffman
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

10.  The detection of respiratory syncytial virus in nasopharyngeal aspirates: assessment, formulation, and evaluation of monoclonal antibodies as a diagnostic reagent.

Authors:  A Freke; E J Stott; A P Roome; E O Caul
Journal:  J Med Virol       Date:  1986-02       Impact factor: 2.327

View more
  24 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

3.  Influenza vaccination in adults with cystic fibrosis.

Authors:  E L Ong; D Bilton; J Abbott; A K Webb; R A McCartney; E O Caul
Journal:  BMJ       Date:  1991-09-07

4.  Differential responses to rhinovirus- and influenza-associated pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Ixsy A Ramirez; Lindsay J Caverly; Lindsay L Caverly; Linda M Kalikin; Adam M Goldsmith; Toby C Lewis; David T Burke; John J LiPuma; Uma S Sajjan; Marc B Hershenson
Journal:  Ann Am Thorac Soc       Date:  2014-05

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Authors:  Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

7.  Acute severe deterioration in cystic fibrosis associated with influenza A virus infection.

Authors:  S P Conway; E J Simmonds; J M Littlewood
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

8.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.

Authors:  H K Johansen; N Høiby
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

9.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

10.  The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis.

Authors:  Megan W France; Szeanna Tai; Phillip J Masel; Vanessa L Moore; Tracy L McMahon; Alexander J Ritchie; Scott C Bell
Journal:  BMC Pulm Med       Date:  2010-02-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.